<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04220255</url>
  </required_header>
  <id_info>
    <org_study_id>MC_Liberty677MY_HU_2019</org_study_id>
    <nct_id>NCT04220255</nct_id>
  </id_info>
  <brief_title>Clinical Outcome at 5 Years After Implantation of the Liberty677MY Multifocal Intraocular Lens</brief_title>
  <official_title>Clinical Outcome at 5 Years After Implantation of Medicontur Multifocal Intraocular Lens Liberty 677MY: Visual Outcomes, Patients' Satisfaction, YAG Capsulotomy Rate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicontur Medical Engineering Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medicontur Medical Engineering Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess visual outcomes, light disturbances and patients' satisfaction after&#xD;
      implantation with the Liberty677MY multifocal IOL, as well as protection of PCO development&#xD;
      within 5 year follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Liberty677MY multifocal IOL is designed for restoring near, intermediate and distance&#xD;
      vision. The technology of Liberty 677MY is based on the elevated phase shift technology&#xD;
      (patent pending). Previous evaluations showed the strength of studied IOL both in laboratory&#xD;
      and clinical conditions.&#xD;
&#xD;
      Patients will be examined 5 years after implantation. The examination will include the&#xD;
      measurement of the best corrected distance, intermediate and near visual acuity (assessed&#xD;
      with Early Treatment Diabetic Retinopathy Study (ETDRS) charts), intraocular pressure&#xD;
      (contact Goldman tonometry), biomicroscopic and fundocsopic examination, contrast sensitivity&#xD;
      (CSV-1000), defocus curve, reading capability, pupilometry in different light conditions and&#xD;
      PCO evaluation, Nd:YAG capsulotomy rate, photo-documentation of anterior segment. YAG&#xD;
      capsulotomy will be indicated in case of posterior capsule opacification (PCO). The criteria&#xD;
      for YAG capsulotomy will be visual acuity decreased 2 or more lines when using (ETDRS)&#xD;
      charts. Details of all related and unrelated complications will be documented, including&#xD;
      severity, time of onset, specific treatment and clinical outcome. The investigators will also&#xD;
      record whether the capsulorhexis is on or partially off the optic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Uncorrected Decimal VA (6 m)</measure>
    <time_frame>5 years after implantation</time_frame>
    <description>Visual acuity (VA) was tested monocularly (each eye separately) and binocularly (both eyes together) 5 years after implantation, unaided at a distance of 6 meters (m) using Early Treatment Diabetic Retinopathy ( ETDRS) charts and assessed in logarithm of the minimum angle of resolution (LogMAR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Uncorrected Decimal VA (60 cm)</measure>
    <time_frame>5 years after implantation</time_frame>
    <description>Visual acuity (VA) was tested monocularly (each eye separately) and binocularly (both eyes together) 5 years after implantation, unaided at a distance of 60 centimeters (cm) using ETDRS charts, assessed in LogMAR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Uncorrected Decimal VA (40 cm)</measure>
    <time_frame>5 years after implantation</time_frame>
    <description>Visual acuity (VA) was tested monocularly (each eye separately) and binocularly (both eyes together) 5 years after implantation, unaided at a distance of 40 centimeters (cm) using ETDRS charts, assessed in LogMAR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corrected Decimal VA (6 m)</measure>
    <time_frame>5 years after implantation</time_frame>
    <description>Visual acuity (VA) was tested monocularly (each eye separately) and binocularly (both eyes together) 5 years after implantation, unaided at a distance of 6 meters (m) using ETDRS charts, assessed in LogMAR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corrected Decimal VA (60 cm)</measure>
    <time_frame>5 years after implantation</time_frame>
    <description>Visual acuity (VA) was tested monocularly (each eye separately) and binocularly (both eyes together) 5 years after implantation, unaided at a distance of 60 centimeters (cm) using ETDRS charts , assessed in LogMAR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corrected Decimal VA (40 cm)</measure>
    <time_frame>5 years after implantation</time_frame>
    <description>Visual acuity (VA) was tested monocularly (each eye separately) and binocularly (both eyes together) 5 years after implantation, unaided at a distance of 40 centimeters (cm) using ETDRS charts, assessed in LogMAR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Defocus Curve Profiles</measure>
    <time_frame>5 years after implantation</time_frame>
    <description>Visual acuity measurement (assessed in logarithm of the minimum angle of resolution (LogMAR)) taken with different levels of optical defocus was tested monocularly (each eye separately) and binocularly (both eyes together).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Contrast Sensitivity CSV-1000</measure>
    <time_frame>5 years after implantation</time_frame>
    <description>Binocular Assessment of contrast sensitivity at threshold using the Contrast sensitivity vision (CSV) CSV-1000 in photopic and mesopic conditions with or without glare.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Posterior capsule opacification (PCO) rate</measure>
    <time_frame>5 years after implantation</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cataract</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Liberty677MY Multifocal IOL</intervention_name>
    <description>multifocal intraocular lens (IOL)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pseudophakic patients implanted with Liberty 677MY in 2014-2015 during the study under the&#xD;
        ethical approval: 059823/2014/OTIG&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pseudophakic patients implanted with Liberty 677MY in 2014-2015 during the study under&#xD;
             the ethical approval: 059823/2014/OTIG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diabetic retinopathy&#xD;
&#xD;
          -  iris neovascularisation&#xD;
&#xD;
          -  serious intraoperative complications&#xD;
&#xD;
          -  congenital eye abnormality&#xD;
&#xD;
          -  glaucoma&#xD;
&#xD;
          -  pseudoexfoliation syndrome&#xD;
&#xD;
          -  amblyopia&#xD;
&#xD;
          -  uveitis&#xD;
&#xD;
          -  long-term anti-inflammatory treatment&#xD;
&#xD;
          -  AMD (advanced AMD)&#xD;
&#xD;
          -  retinal detachment&#xD;
&#xD;
          -  prior ocular surgery in personal medical history (except cataract surgery aiming the&#xD;
             implantation of the multifocal IOL)&#xD;
&#xD;
          -  previous laser treatment&#xD;
&#xD;
          -  corneal diseases&#xD;
&#xD;
          -  severe retinal diseases (dystrophy, degeneration)&#xD;
&#xD;
          -  severe myopia (if required IOL power is lower than 10 D)&#xD;
&#xD;
          -  inadequate visualization of the fundus on preoperative examination&#xD;
&#xD;
          -  patients deemed by the clinical investigator because of any systemic disease.&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  eye trauma in medical history&#xD;
&#xD;
          -  current use of systemic steroids or topical ocular medication&#xD;
&#xD;
          -  preoperative smaller pupil size of 6 mm under topical mydriasis&#xD;
&#xD;
          -  kappa angle &gt;5°&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Retinaszervíz Kft</name>
      <address>
        <city>Veszprém</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2020</study_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

